| Title: | Incident chronic kidney disease risk and the predictive value of the uric acid-to-HDL ratio in lean and non-lean MASLD: a prospective cohort and multi-omics study |
| Journal: | International Urology and Nephrology |
| Published: | 9 Aug 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/42572097/ |
| DOI: | https://doi.org/10.1007/s11255-026-05325-8 |
Publication 21033
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundAlthough metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for chronic kidney disease (CKD), validated clinical markers for individualized renal risk stratification remain limited, especially in lean patients. Therefore, we aimed to evaluate an accessible index to predict this risk and explore the underlying pathophysiological mechanisms.MethodsWe investigated incident CKD risk among UK Biobank participants across a biomarker-based FLI cohort (N = 353,325) and an imaging-based MRI-PDFF cohort (N = 33,155). The participants with MASLD were stratified into lean and non-lean groups. We then evaluated uric acid to HDL ratio (UHR) as a continuous proxy to assess metabolic-related renal risk, and integrated Mendelian randomization (MR), plasma proteomics, and single-cell RNA sequencing to identify circulating mediators.ResultsWhile non-lean MASLD consistently increased CKD risk, the risk in lean MASLD differed by metabolic status. FLI-defined lean MASLD, characterized by severe metabolic abnormalities, predicted a higher incident CKD risk, whereas MRI-defined lean MASLD with milder metabolic traits showed no such association. Furthermore, UHR showed a dose-response relationship with CKD and provided better predictive value than the TyG index. MR analyses revealed that MASLD increases CKD risk indirectly through metabolic burden. Integrative multi-omics analyses suggested AHSG and CPB2 as potential circulating markers of this metabolic-renal axis.ConclusionsIn MASLD, the severity of systemic metabolic burden is a key determinant of incident CKD risk across both lean and non-lean individuals. To quantify this burden, UHR serves as a robust continuous proxy that provides better renal risk stratification than the TyG index for both lean and non-lean patients. Furthermore, AHSG and CPB2 represent potential circulating biomarkers for this metabolic-renal link.</p>
19 Authors
- Yuting Zhang
- Shurong Liu
- Zijian Huang
- Shuting Song
- Shengjia Xu
- Chaofeng Guan
- Yajing Chen
- Ming Song
- Peilin Pang
- Wenrun Wu
- Sailun Wang
- Xiaoli Chen
- Lin Zhang
- Liang Zheng
- Qian Zhao
- Baktybek Kojonazarov
- Yuzhen Zhang
- Jie Liu
- Gang Zhao
1 Application
| Application ID | Title |
|---|---|
| 656613 | Large-scale plasma proteomics analysis in the UK Biobank for improved prediction of cardiovascular disease risk in a population without prior cardiovascular events |
Enabling scientific discoveries that improve human health